Mayo Clinic | Strategic Alliance Partners

Stephen M. Ansell, MD, PhD, of Mayo Clinic, discusses studies exploring PD-1 inhibitors in Hodgkin lymphoma, specifically the CheckMate-039 trial.

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the recent expansion of treatment options available for patients with colorectal cancer.

The NCCN recently published new guidelines for myeloproliferative neoplasms (MPNs), with an emphasis on diagnosis, treatment, and supportive care strategies for myelofibrosis. Subsequent editions will focus more on other MPNs, including essential thrombocythemia, polycythemia vera.

Treatment for patients with aggressive lymphomas needs to be intensified with more effective strategies, potentially including an infusion, dose-adjusted regimen of etoposide phosphate, prednisone, vincristine sulfate, cyclophosphamide, doxorubicin hydrochloride, and rituximab.

Ruben A. Mesa, MD, chair of Hematology, Mayo Clinic, discusses updates that are expected in 2017 to the NCCN Guideline for Myeloproliferative Neoplasms (MPNs).

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses his vision for the future treatment landscape of multiple myeloma.

Rafael Fonseca, MD, professor of Medicine, Mayo Clinic, discuses the recent FDA approval of daratumumab (Darzalex) in combination with lenalidomide and dexamethasone or bortezomib (Velcade) and dexamethasone for patients with relapsed multiple myeloma following at least 1 prior therapy.

Investigators are exploring therapy options for patients with indolent lymphomas—including follicular lymphoma, marginal zone lymphoma, and small lymphocytic lymphoma—as rituximab regimens are proving to not be a long-term option for many patients.

Standard treatment approaches for patients with chronic lymphocytic leukemia will continue to include fludarabine, cyclophosphamide, and rituximab and allogeneic stem cell transplantation.

Jose Leis, MD, associate professor of Medicine, Mayo Clinic, discusses treatment-related advances in the field of chronic lymphocytic leukemia (CLL) over the last several decades in an interview during the 2016 OncLive State of the Science Summit on Hematologic Malignancies.

Ruben A. Mesa, MD, chair, Division of Hematology and Medical Oncology, deputy director, professor of Medicine, Mayo Clinic, discusses the NCCN guidelines for treatment of patients with myeloproliferative neoplasms (MPNs).

Rafael Fonseca, MD, professor of Medicine, Mayo Clinic, discusses some of the ongoing clinical trials that could be potentially practice changing for the treatment of patients with multiple myeloma.

Craig B. Reeder, MD, assistant professor of Medicine, Mayo Clinic, discusses the role that R-CHOP will continue to have in the treatment of patients with aggressive lymphomas.

Allison C. Rosenthal, DO, hematology consultant, Mayo Clinic, discusses some of the treatment strategies for patients with indolent lymphomas.

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses dosing strategies with regorafenib (Stivarga) in patients with colorectal cancer (CRC).

Keith C. Bible, MD, PhD, discusses novel treatments he is excited about, the role of lenvatinib, and what the future may hold for thyroid cancer treatment.

S. Vincent Rajkumar, MD, professor of Medicine at Mayo Clinic, discusses the significance of the phase III SWOG S0777 study, which looked at bortezomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with previously untreated multiple myeloma.

Judy C. Boughey, MD, chair, Division of Surgery Research, Mayo Clinic, discusses the surgical approach for patients with HER2-positive breast cancer.

Richard Joseph, MD, discusses the challenges of treating mucosal melanoma and what oncologists need to know prior to using immunotherapies for the treatment of both mucosal and cutaneous melanomas.

S. Vincent Rajkumar, MD, discusses a trial of bortezomib, lenalidomide, and dexamethasone versus lenalidomide plus dexamethasone in patients with previously untreated multiple myeloma.

Shaji Kumar, MD, discusses how newly approved agents and other changes have affected the treatment of multiple myeloma and what is on the horizon for the disease.

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, gives an overview on the expanded definition of multiple myeloma.

Judy C. Boughey, MD, chair, Division of Surgery Research, Mayo Clinic, discusses locoregional clinical trials for breast cancer.

Renal cell carcinoma with sarcomatoid differentiation, a histology that is often resistant to targeted therapies and interleukin-2 immunotherapy (IL-2), may respond to anti–PD-1/PD-L1 therapies.

Frank A. Sinicrope, MD, medical oncologist, Departments of Gastroenterology and Hepatology and Oncology, Mayo Clinic, discusses patients with metastatic colorectal cancer (mCRC) who are mismatch repair-deficient.

Asher A. Chanan-Khan, MD, chair, Hematology/Oncology, Mayo Clinic in Florida, discusses ibrutinib as a backbone of treatment for patients with chronic lymphocytic leukemia (CLL).

Grzegorz S. Nowakowski, MD, responds to questions raised regarding the use of immunohistochemistry in his phase II study, as well as future plans for the investigation of R2-CHOP in non-GCB DLBCL.

Ruben A. Mesa, MD, deputy director, Mayo Clinic, discusses the intended patient population with myelofibrosis and low platelet counts for pacritinib.

Aleksandar Sekulic, MD, PhD, chief resident associate, Dermatology, Clinician Investigator Training Program, Mayo Clinic, discusses the rationale for molecular testing in patients with advanced melanoma.

Lead author Asher A. Chanan-Khan, MD, discusses the HELIOS trial, in which adding ibrutinib to bendamustine and rituximab lowered the risk of disease progression by 80% in patients with CLL.